<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of brain insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in neuroprotection was further investigated using in vitro and in vivo models of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> by assessing the effects of IGF-I, IGF-II, and high affinity IGFBP ligand inhibitors (the <z:chebi fb="7" ids="16670">peptide</z:chebi> [Leu24, 59, 60, Ala31]hIGF-I (IGFBP-LI) and the small molecule NBI-31772 (1-(3,4-dihydroxybenzoyl)-3-<z:chebi fb="0" ids="29326">hydroxycarbonyl</z:chebi>-6, 7-dihydroxyisoquinoline), which pharmacologically displace and elevate endogenous, bioactive IGFs from IGFBPs </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment with IGF-I, IGF-II, or IGFBP-LI (2 microg/mL) significantly (P &lt; 0.05) reduced CA1 damage in organotypic hippocampal cultures resulting from 35 minutes of oxygen and <z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation by 71%, 60%, and 40%, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>In the subtemporal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, intracerebroventricular (icv) administration of IGF-I and IGF-II at the time of <z:mp ids='MP_0006134'>artery occlusion</z:mp> reduced ischemic brain damage in a dose-dependent manner, with maximum reductions in total <z:mpath ids='MPATH_124'>infarct</z:mpath> size of 37% (P &lt; 0.01) and 38% (P &lt; 0.01), respectively </plain></SENT>
<SENT sid="3" pm="."><plain>In this model of MCAO, i.c.v. administration of NBI-31772 at the time of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> also dose-dependently reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size, and the highest dose (100 microg) significantly reduced both total (by 40%, P &lt; 0.01) and cortical (by 43%, P &lt; 0.05) <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="4" pm="."><plain>In the intraluminal suture MCAO model, administration of NBI-31772 (50 microg i.c.v.) at the time of <z:mp ids='MP_0006134'>artery occlusion</z:mp> reduced both cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (by 40%, P &lt; 0.01) and <z:e sem="disease" ids="C1527311" disease_type="Disease or Syndrome" abbrv="">brain swelling</z:e> (by 24%, P &lt; 0.05), and it was still effective when treatment was delayed up to 3 hours after the induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>These results further define the neuroprotective properties of IGFs and IGFBP ligand inhibitors in experimental models of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>